NDAOTICSUSPENSION/DROPS
Approved
Feb 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
CIPRO HC (ciprofloxacin hydrochloride and hydrocortisone) by Novartis is corticosteroid hormone receptor agonists [moa]. Approved for corticosteroid [epc]. First approved in 1998.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CIPRO HC is a fixed-dose otic suspension combining ciprofloxacin (fluoroquinolone antibiotic) and hydrocortisone (corticosteroid) for topical ear treatment. It is indicated for bacterial ear infections with inflammation, delivering both antimicrobial and anti-inflammatory action directly to the affected tissue. The hydrocortisone component acts as a corticosteroid hormone receptor agonist to reduce pain and inflammation associated with otitis.
$0.04MPart D
LOE ApproachingDeclining
Declining Part D spending and low claim volume signal a mature, niche product with minimal team expansion potential; commercial roles would focus on maintaining existing market share rather than growth initiatives.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CIPRO HC offers limited career growth potential given its LOE-approaching status, minimal spending ($40K Part D), and zero linked job opportunities. Roles would emphasize defensive strategies (generic competition, price protection) rather than growth initiatives, making this a short-term assignment for professionals seeking experience in mature product management or market access.
Brand Manager
Worked on CIPRO HC at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.